in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period withglucagon-like peptide-1 or exendin-4. Diabetes2002;51:1443–1452. 20. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B: Glucagon-like peptide-1 and exendin-4 stimulatebeta-cell neogenesis in streptozotocin-treated new-born rats resulting in persistently improved glucosehomeostasis at adult age. Diabetes 2001;50:1562–1570. 21. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B: Exendin-4 is a high potency agonistand truncated exendin-(9–39)-amide an antagonist atthe glucagon-like peptide 1-(7–36)-amide receptor ofinsulin-secreting beta-cells. J Biol Chem 1993;268:19650–19655. 22. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlledclinical trial. Biometrics 1975;31:103–115. 23. World Medical Association Declaration of Helsinki.